India, March 31 -- Genmab A/S (GMAB) announced that the European Commission (EC) has granted marketing authorization for TIVDAK (tisotumab vedotin) as a monotherapy for adult patients with recurrent or metastatic cervical cancer who have experienced disease progression following systemic therapy.
This approval marks TIVDAK as the first and only antibody-drug conjugate (ADC) authorized for this patient population in the European Union. Despite advancements in cervical cancer prevention and early detection, the need for additional treatment options remains significant, particularly for advanced-stage cases. Cervical cancer ranks as the fourth most common cause of cancer-related deaths among women globally and the 11th most frequent cancer am...